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  33 
Abstract 34 
Context: Novel small molecule inhibitors of the oxytocin receptor (OTR) may have distinct 35 
pharmacology and mode of action when compared to first generation oxytocin antagonists 36 
when used for the prevention of preterm birth.  37 
Objective: To determine the mechanism of action of small molecule OTR antagonists 38 
retosiban and epelsiban in comparison to the currently used peptide-based compound atosiban. 39 
Design: Human myometrial samples were obtained at cesarean section and subjected to 40 
pharmacological manipulations to establish the effect of antagonist binding to OTR on 41 
downstream signaling. 42 
Results: Retosiban antagonism of oxytocin action in human myometrium was potent, rapid 43 
and reversible. Inhibition of inositol 1,4,5-trisphosphate (IP3) production followed single site 44 
competitive binding kinetics for epelsiban, retosiban and atosiban. Retosiban inhibited basal 45 
production of IP3 in the absence of oxytocin. Oxytocin and atosiban, but not retosiban inhibited 46 
forskolin and calcitonin stimulated cAMP production. Inhibition of cAMP was reversed by 47 
pertussis toxin.  Oxytocin and atosiban, but not retosiban and epelsiban, stimulated ERK1/2 48 
activity in a time a concentration dependent manner. Oxytocin and atosiban stimulated cyclo 49 
oxygenase 2 (COX2) activity and subsequent production of prostaglandin E2 and F2. 50 
Prostaglandin production was inhibited by rofecoxib, pertussin toxin, and ERK inhibitor 51 
U0126.  Oxytocin but not retosiban or atosiban stimulated coupling of the OTR to Gαq G-52 
proteins. Oxytocin and atosiban but not retosiban stimulated coupling of the OTR to Gαi G-53 
proteins.  54 
Conclusions: 55 
Retosiban and epelsiban demonstrate distinct pharmacology when compared to atosiban in 56 
human myometrial smooth muscle. Atosiban displays agonist activity at micromolar 57 
concentrations leading to stimulation of prostaglandin production.  58 
  59 
Introduction 60 
Every year an estimated 15 million babies are born preterm (< 37 weeks of gestation) 61 
accounting for one in ten deliveries [1].  Preterm birth is the leading cause of infant mortality 62 
[2] and morbidity [3] in addition to causing a significant financial burden [4] and remains an 63 
important unmet clinical challenge.  One approach to treat threatened preterm delivery has been 64 
the use of inhibitors of uterine contractility to achieve tocolysis.  65 
Inhibitors licensed for tocolytic use include salbutamol, terbutaline, magnesium sulphate, 66 
ritodrine and atosiban [5].  Atosiban is a peptide antagonist of the vasopressin V1a and OTRs 67 
[6] and is used in tocolytic treatment primarily for its actions on the OTR. Oxytocin is an 68 
important stimulator of the uterus at term [7] acting initially to activate phospholipase C via 69 
Gαq/11 to stimulate production of IP3 and the release of intracellular Ca
2+ from the sarcoplasmic 70 
reticulum [8].   In addition to immediate Ca2+ release in myometrial cells oxytocin can also 71 
stimulate longer term inflammation in the myometrium and fetal membranes via nuclear factor 72 
kappa-light-chain-enhancer of activated B cells (NF-B) [9], an effect mimicked by 73 
micromolar concentrations of atosiban, and blocked by the Gαi inhibitor, pertussis toxin [10]. 74 
The structure of atosiban is based on the peptide structure of oxytocin and it is unclear whether 75 
the second generation of small molecule antagonists, such as retosiban, which demonstrate 76 
greater selectivity for the OTR [11,12], also demonstrate agonist activity via Gαi at higher 77 
concentrations.  Furthermore, retosiban has exhibited unexpected properties in experimental 78 
studies, intimating that its pharmacology may be different to that of atosiban. For example, 79 
retosiban inhibits stretch induced ERK signaling in myometrial explants [13]. In phase 2 trials, 80 
a single dose of retosiban significantly delayed threatened preterm labour for more than one 81 
week, suggesting a mechanism of action which outlasts the presence of the compound in the 82 
blood [14].  In the current study, we sought to determine the pharmacological mechanism of 83 
action of retosiban in comparison to atosiban using a combination of in vitro approaches in 84 
both human myometrium and recombinant mammalian expression systems.   85 
Material and Methods 86 
Ethical Approval 87 
All procedures involving women were conducted within the guidelines of The Declaration of 88 
Helsinki and were subject to local ethical approval (REC-05/Q2802/107). Written informed 89 
consent for sample collection was obtained prior to surgery. 90 
Subject criteria and selection 91 
Subjects were recruited into a single group at elective caesarean section between 38-40 weeks 92 
gestation. Subjects were not in labour (NIL), as defined by an absence of observable signs of 93 
labour including regular contractions (<3min apart), membrane rupture and cervical dilatation 94 
(>2cm) with no augmentation. 95 
Sample collection 96 
Myometrial biopsies were collected at caesarean section by knife biopsy from the lower uterine 97 
segment incision and were obtained prior to administration of oxytocin. Samples were briefly 98 
washed in saline and flash frozen in LN2, or placed in modified Krebs’-Henseleit (m-KHB) 99 
solution (composition (mM): NaCl; 133, KCl; 4.7, Glucose; 11.1, MgSO4; 1.2, KH2PO4; 1.2, 100 
CaCl; 2.5, TES; 10, pH 7.4) for contraction studies. 101 
Cell culture 102 
Primary myometrial cell cultures were established from whole biopsies by digestion of the 103 
extracellular matrix. Primary myocytes were isolated by 2 mg/ml collagenase (Type IV, Fisher 104 
Scientific, Loughborough, UK) digestion in DMEM for 1 h at 37°C and mechanical isolation 105 
through fire-polished glass pipettes. Freshly isolated myocytes were cultured in DMEM 106 
supplemented with 10% FCS and penicillin (100 IU/ml) and streptomycin (100 μg/ml). 107 
Chinese Hamster Ovary cells recombinantly expressing the human OTR (CHO-hOTR) cells 108 
were obtained from GlaxoSmithKline and were routinely maintained in F-12 media 109 
supplemented with 10% FCS, penicillin (100 IU/ml) and streptomycin (100 μg/ml). All cells 110 
were cultured at 37°C in a 95%/5% air/CO2-humidified environment. Cells were sub-cultured 111 
at 80% confluency by lifting with 0.05% trypsin, and not used beyond passage 3. 112 
Organ bath studies 113 
Muscle strips approximately 10×2×2mm were mounted vertically in 10ml organ bath chambers 114 
in m-KHB and 95% air/5% CO2 for isometric force recordings. Force was measured with 115 
FT03C transducers (Grass Instrument Co, Quincy, MA, USA) and recorded digitally with 116 
MacLab Chart software (ADInstruments Ltd, Oxfordshire, UK). Strips were held under 20 mN 117 
tension for 90-120 min wherein rhythmical, spontaneous contractions developed. Strips that 118 
failed to contract spontaneously were excluded. For competitive antagonism, full oxytocin-119 
mediated concentration-response curves were generated in the presence of varying 120 
concentrations of retosiban or atosiban. Each dose of oxytocin was added for 10 min and 121 
separated by 20 min washing. Data analysis: Peak responses, peak frequency and area under 122 
the curve (integral) were calculated using MacLab Chart software from the basal and dosing 123 
periods. Changes in contractions were expressed as a percentage increase over basal and plotted 124 
using GraphPad Prism (v5.0) software. 125 
Radioligand binding 126 
Tissue preparation: Frozen tissue was ground to a fine powder using a pestle and mortar and 127 
homogenised in ice-cold radioligand binding buffer (composition (mM): Tris-HCl; 50, EDTA; 128 
2.5, and MgSO4; 5, pH 7.4 (with KOH)). Homogenates were cleared (1000 rpm, 10 min 4
°C), 129 
pelleted (15000 rpm, 15 min, 4°C) and resuspended in radioligand binding buffer where protein 130 
was adjusted to 1 mg/ml. Radioligand binding assay: Assays were performed in 500 μl volumes 131 
of radioligand binding buffer containing ~100 μg membranes and [3H]-Oxytocin (SA: 50 132 
μCi/mmol) (Perkin Elmer. Massachusetts, U.S.A.) at concentrations ranging from 0.001-50 133 
nM. Non-specific binding was determined by the inclusion of 100 nM unlabeled oxytocin. 134 
Assays were equilibrated at 30°C for 2h before harvest through 0.5% polyethylenimine pre-135 
soaked Whatman GF/B filters. Recovered radiation was determined by standard liquid 136 
scintillation counting. Data analysis: Specific binding was determined as total binding less non-137 
specific binding. Data were fitted using GraphPad Prism (v5.0) and the Bmax and KD values 138 
obtained. 139 
Measurement of cAMP  140 
cAMP was determined using the 2-step HTRF cAMP kit (Cisbio Bioassay, Codolet, France). 141 
Cell culture and agonist stimulation: Cells were seeded in 96-well plates at a density 20000 142 
cells/well and, where applicable, treated with 100 ng/ml pertussis toxin (PTX) for 18h. Cells 143 
were washed in m-KHB containing 300 µM 3-isobutyl-1-methylxanthine (IBMX) and 144 
equilibrated in buffer at 37°C for 15 min. For Gαs experiments, cells were stimulated directly 145 
with compounds as required, and for assessment of Gαi signaling, cells were stimulated for 146 
time period indicated prior to challenge with forskolin (FSK) (10 µM, 10 min). Assays were 147 
terminated by addition of 25 µl kit-supplied lysis buffer. Detection of cAMP: 10 µl from each 148 
well was transferred in duplicate to white, low volume 384-well plates (Corning®) and 149 
detection of cAMP proceeded exactly as per manufacturer’s instructions (CisBio) with 150 
fluorescence determined on a PHERstar FS plate reader (BMG Labtech). Data analysis: cAMP 151 
levels in each well were interpolated from a 4-parameter fit of known standards (Microsoft 152 
Excel) and plotted graphically using GraphPad Prism (v5.0). 153 
Measurement of phosphorylated ERK (pERK) in cells 154 
Levels of phosphorylated ERK were determined using the HTRF Cellul’ERK assay kit (Cisbio 155 
Bioassay, Codolet, France) as per manufacturer’s instructions. Cell stimulation and lysis: 156 
Myometrial cells were seeded in 96-well plates at a density 5000 cells/well and cultured 157 
overnight before serum-starvation for 24h. Where appropriate, cells were pre-treated with 100 158 
ng/ml PTX for 18h. Cells were washed in m-KHB and equilibrated in buffer at 37°C for 30min. 159 
Cells were challenged with compounds for time points indicated before aspiration and addition 160 
of 50 µl supplied-lysis buffer (containing phosphatase inhibitors) for 30 min (RT). Detection 161 
of pERK: 16 µl of each well was transferred in duplicate to white, low volume 384-well plates 162 
(Corning®) for detection of pERK as per the Cellul’ERK assay manufacturer’s instructions 163 
with fluorescence determined on a PHERstar FS plate reader. Data analysis: Increases in pERK 164 
were calculated as % increase over basal (vehicle, unstimulated) cells.  165 
Measurement of PGE2, PGF2 and protein kinase A (PKA) in myometrial strips 166 
Muscle strips approximately 5×2×2 mm were mounted horizontally in a DMT Flatbed muscle 167 
strip myograph system (DMT, Hinnerup, Denmark). Strips were held under 20 mN tension in 168 
m-KHB at 37°C wherein spontaneous contractions occurred. Drugs were added directly into 169 
the organ bath as per protocol requirements. Tissue was snap frozen by rapid removal from 170 
organ baths and immediate submersion into LN2. Concurrently, aliquots of the supernatant 171 
were collected for assessment of prostaglandin production. Where necessary, tissue biopsies 172 
were treated with 100 ng/ml PTX overnight at 4°C to inhibit Gαi signaling, or 1h pre-treatment 173 
with 10 μM U0126 to inhibit ERK signaling or 10 μM rofecoxib to inhibit COX-2. Preparation 174 
of cell lysates: Frozen tissue was diced into small pieces before homogenisation in 1 ml RIPA 175 
buffer containing protease (Pierce™ tablets) and phosphatase (phosphatase inhibitor cocktail 176 
2 (diluted 1:100), (Sigma, Poole, UK)) inhibitors. Homogenisation was achieved using a NEXT 177 
Advanced BBY24M Bullet Blender Storm (Next Advanced, Averill Park, NY, USA) for 10min 178 
at 4°C, and the NAVY ball bearing mix (refer to manufacturer’s instructions). Lysates were 179 
subject to clearance (500 rpm, 2 min, 4°C) before transfer to duplicate tubes for assay and 180 
protein quantification via a modified Lowry assay (DC™ Protein Assay, Bio-Rad, CA, 181 
U.S.A.). Quantitation of PGE2 and PGF2 in tissue supernatant was via competitive ELISA 182 
exactly as per manufacturers’ instructions. The PGE2 assay (KGE0048) was obtained from 183 
R&D Systems (Minneapolis, MN, USA), and the PGF2 assay (516011) from Cayman 184 
Chemicals (Ann Arbor, MI, USA). Tissue homogenates were assessed for PKA using a PKA 185 
activity assay from Arbor Assays (K027-H1) and COX-2 by sandwich ELISA using 186 
(DYC4198-2) from R&D Systems (Minneapolis, MN, USA). Data analysis: In all cases, 187 
samples were extrapolated from known standards using a 4-parameter fit curve in GraphPad 188 
prism. PGE2 and PGF2 production, PKA activity and COX-2 levels were related to protein 189 
content. 190 
[35S]-guanosine 5’-O-[gamma-thio]triphosphate ([35S]GTPγS) binding 191 
[35S]-GTPγS is a non-hydrolyzable analog of GTP that stays bound to activated G-proteins. 192 
Specific G-protein activation can therefore be detected by virtue of the radiolabel, and co-193 
immunoprecipitation with specific Gα antibodies. The [35S]-GTPγS assay was performed 194 
according to a modification of methodologies described previously[15-18] Membrane 195 
preparation: Primary myometrial cultures and CHO-hOTR cells were grown to confluence in 196 
175cm2 flasks, lifted and pelleted via standard cell culture techniques. Pelleted cells were 197 
homogenized in the presence of hypotonic lysis buffer (10 mM EDTA, 10 mM HEPES, pH 198 
7.4) using a Coleman handheld homogenizer. The homogenate was pre-cleared by 199 
centrifugation (500 g, 5 min, 4°C) and the membranes collected via centrifugation (36,000g, 200 
30 min, 4°C). Membranes were resuspended in freezing buffer (10 mM HEPES, 0.1 mM 201 
EDTA, pH 7.4) at 6 mg/ml protein and rapidly frozen in liquid nitrogen. Membranes were 202 
stored at -80°C until used. Receptor activation: Frozen membrane aliquots were diluted to 1.5 203 
mg/ml in assay buffer (composition: (mM): HEPES; 10, NaCl; 100, MgCl2; 10, pH 7.4) and 204 
75 µg membrane were added to 50 µl of assay buffer containing 1 nM [35S]-GTPγS (1250 Ci 205 
mmol-1) and 1 µM GDP, with or without ligands as required, and incubated at 30°C for 2 min. 206 
Non-specific binding was determined by the inclusion of 10 µM unlabeled GTPγS. Incubations 207 
were terminated by 900 µl ice-cold assay buffer and transfer to ice. Cell membranes were 208 
recovered from the reaction mixture by centrifugation (20,000g, 6 min, 4°C) and the 209 
supernatant removed by aspiration. Membrane pellets were solubilized by the addition of 50 210 
µl ice-cold solubilization buffer (composition (mM): Tris/HCl; 100, NaCl; 200, EDTA; 1 and 211 
1.25% (v:v) Igepal CA 630, pH 7.4) containing 0.2% (w:v) SDS and vortex-mixing. Once the 212 
protein was completely solubilized, an equal volume of solubilization buffer without SDS was 213 
added. Immuno-detection of G-Proteins: The solubilized protein was pre-cleared with normal 214 
rabbit serum (1:100 dilution) and 30 µl of Protein-G sepharose beads (protein-G sepharose 215 
bead suspension 30% w:v in TE buffer (10 mM Tris/HCl, 10 mM EDTA, pH 8.0)) for 60 min 216 
at 4°C. The protein-G beads and any insoluble material were collected by centrifugation 217 
(20,000g, 6 min, 4°C) then 100 µl of the supernatant was transferred to a fresh tube containing 218 
G-protein antiserum (1:100 dilution). Samples were vortex-mixed and rotated overnight at 4°C. 219 
To each sample tube was added 70 µl of Protein G-sepharose bead suspension and the samples 220 
vortex-mixed and rotated for 90 min at 4°C. Protein G-sepharose beads were pelleted at 20,000 221 
g and supernatant removed. Beads were washed and pelleted three times with 500 µl 222 
solubilization buffer (less SDS) before re-suspension in scintillation cocktail where [35S]-223 
GTPγS was determined by standard liquid scintillation counting methods. Data analysis: CPM 224 
values were expressed as a % increase over basal (unstimulated). 225 
IP-One assay 226 
The HTFR IP-One assay was performed exactly as per manufacturer’s instruction (CisBio). 227 
Briefly, Cells were seeded at 50,000 cells well-1 in white, low volume, 384-well plates 228 
(Corning®). On day of assay, cells were washed with stimulation buffer (provided with kits) 229 
and left with 7 µl buffer per well. Duplicate ligand plates were made containing double the 230 
desired concentrations of antagonist, agonist or vehicle as required and cells stimulated by 231 
direct transfer of 7 µl to corresponding wells on the assay plate. Cells were stimulated for 1 h, 232 
at 37°C, before reactions were terminated and fluorescence determined on a PHERstar FS plate 233 
reader (BMG Labtech). Data analysis: IP-1 levels in each well were interpolated from a 4-234 
parameter fit of known standards (Microsoft Excel) and plotted graphically using GraphPad 235 
Prism (v5.0), from where EC50 values were obtained. To determine antagonist potency, pA2 236 
values were determined from the intercept when y=0 using the Schild equation (Log (EC50 237 
ratio -1) vs. Log [antagonist]). 238 
Measurement of IP3 in myometrial strips 239 
Muscle strips were mounted horizontally in a flatbed muscle strip myograph as described above 240 
with drugs added directly into the organ bath. Tissue was snap frozen at critical points by rapid 241 
removal from baths and immediate submersion into LN2. Critical points included the peak of 242 
a spontaneous contraction, midway between spontaneous contractions, peak of oxytocin-243 
mediated contraction and during inhibition of contraction in the presence of retosiban and 244 
atosiban. Frozen tissue was mechanically ground into a fine powder by pestle and mortar and 245 
homogenized in 1M trichloroacetic acid (TCA) for 10 min at 4°C in a Bullet Blender Storm 246 
(Next-Advanced, New York, USA). 400 μM TCA was transferred to tubes and 50 µl 10 mM 247 
EDTA added. TCA was extracted by addition of 1 ml 1:1 (v:v) dilution of tri-n-248 
octylamine:1,1,2-trichlorotrifluoroethane and vigorous mixing. After 10 min, tubes were 249 
centrifuged (1000 rpm 2 min, RT) and 400 µl of top aqueous phase transferred to duplicate 250 
tubes where 50 µl 50mM NaHCO3 was added. Determination of IP3. IP3 levels were determined 251 
using the [3H]-IP3 Radioreceptor assay kit (PerkinElmer Life Inc, Boston, MA) as per the 252 
manufacturer’s instructions. All dilutions were considered and IP3 was calculated in pmol/mg 253 
protein. 254 
Protein determination:  255 
Unless otherwise stated, protein content was assessed by the Bradford method [19]. 256 
Statistical analysis 257 
Contractility studies: 258 
Experiments were repeated on biopsies obtained from different women where n represents the 259 
number of biological replicates. For figures 1 and 2 data were analysed by one-way ANOVA 260 
followed by Dunnett post hoc test comparing test compound to vehicle, and P < 0.05 261 
considered significant. For figure 3 data were analysed by mixed model ANOVA with 262 
antagonist as the between measures variable followed by Dunnett post hoc test comparing test 263 
antagonist concentration to vehicle, and P < 0.05 considered significant. P values were 264 
graphically represented as * P < 0.05, ** P < 0.01, *** P < 0.001. For figure 4 data were 265 
analysed by paired T-Test comparing observations before and after retosiban treatment, and P 266 
< 0.05 considered significant. 267 
IP1 assay: 268 
Experiments were repeated on CHO-hOTR cells where n represents the number of technical 269 
replicates. For figure 5 data were analysed by mixed model ANOVA with antagonist as the 270 
between measures variable followed by Dunnett post hoc test comparing test antagonist 271 
concentration to vehicle, and P < 0.05 considered significant. P values were graphically 272 
represented as * P < 0.05, ** P < 0.01, *** P < 0.001. IP-1 levels were interpolated from a 4-273 
parameter fit of known standards and plotted graphically for calculations of EC50 values using 274 
GraphPad Prism (v5.0). For antagonist potency, pA2 values were determined from the intercept 275 
when y=0 using the Schild equation (Log (EC50 ratio -1) vs. Log [antagonist]). 276 
IP3 assay: 277 
Experiments were repeated on myometrial membrane preparations from different women 278 
where n represents the number of biological replicates. For figure 6 data were analysed by one-279 
way ANOVA followed by Dunnett post hoc test comparing test compound to vehicle, and P < 280 
0.05 considered significant. Refractory period and peak contraction were analysed separately.  281 
P values were graphically represented as * P < 0.05, ** P < 0.01. 282 
cAMP assay: 283 
Experiments were repeated on CHO-hOTR cells where n represents the number of technical 284 
replicates. For figure 7 data were analysed by two-way ANOVA followed by Dunnett post hoc 285 
test comparing test compound time series to vehicle, and P < 0.05 considered significant. P 286 
values were graphically represented as * P < 0.05, ** P < 0.01, *** P < 0.001.  287 
ERK assay: 288 
Experiments were repeated on primary human myometrial cultures derived from different 289 
patient biopsies where n represents the number of biological replicates. For figure 8 data were 290 
analysed by two-way ANOVA followed by Dunnett post hoc test comparing test compound 291 
time series to vehicle, and P < 0.05 considered significant. P values were graphically 292 
represented as * P < 0.05, ** P < 0.01, *** P < 0.001. 293 
COX-2, PKA, PGE2 and PGF2 assay: 294 
Experiments were repeated on biopsies obtained from different women where n represents the 295 
number of biological replicates.  For figure 9 data were analysed by two-way ANOVA 296 
followed by Dunnett post hoc test comparing test compound time series to vehicle, and P < 297 
0.05 considered significant. P values were graphically represented as * P < 0.05, ** P < 0.01. 298 
For figure 10 data were analysed by one-way ANOVA with atosiban and oxytocin analysed 299 
separately followed by Dunnett post hoc test comparing inhibitor compound to oxytocin or 300 
atosiban alone, and P < 0.05 considered significant. P values were graphically represented as 301 
* P < 0.05, ** P < 0.01. 302 
G-protein coupling assay: 303 
Experiments were repeated on membrane preparations from primary human myometrial 304 
cultures derived from different patient biopsies where n represents the number of biological 305 
replicates. For figure 11 data were analysed by one-way ANOVA followed by Dunnett post 306 
hoc test comparing test compound to vehicle, and P < 0.05 considered significant. P values 307 
were graphically represented as * P < 0.05, ** P < 0.01.  308 
Results 309 
Prior to detailed studies of the OTR signaling in myometrial strips, we first characterized the 310 
basic physiological responses to oxytocin. The addition of increasing concentrations of 311 
oxytocin to human myometrial smooth-muscle strips evoked a concentration-dependent 312 
increase in the magnitude, integral and frequency of spontaneous contractions (Fig. 1a and b), 313 
whereas no changes were observed by addition of vehicle control (Fig. 1b). Concentration-314 
response analysis (Fig. 1b) revealed EC50 values of: peak -8.224 ± 0.46 (5.9 nM), integral -315 
8.053 ± 0.13 (8.8 nM), and frequency -8.229 ± 0.16 (5.0 nM). In radioligand binding studies, 316 
membranes were prepared from whole muscle biopsies and saturated with [3H]-oxytocin to 317 
permit the quantification of OTR expression. The binding of [3H]-oxytocin to membranes 318 
prepared from biopsies was saturable. Specific binding, as determined by inclusion of 100nM 319 
oxytocin represented approximately 40% of the total binding at a KD concentration of [
3H]-320 
oxytocin. Analysis of saturation binding curves indicated a Bmax value of 8337 ± 931 fmol/mg 321 
protein, and a KD value of 24.15 ± 6.5nM for oxytocin (Fig. 1c).  322 
The saturation studies confirmed previous studies that the OTR reaches high concentrations in 323 
the myometrium at term [20,21]. Under such conditions it is feasible that unliganded receptor 324 
contributes to downstream signaling. Taken together with previous studies suggesting that 325 
retosiban may be an inverse agonist (defined as a ligand that can reduce constitutive receptor 326 
activity)[13], we sought to investigate whether retosiban could reduce spontaneous 327 
contractions in the absence of oxytocin.  The addition of retosiban (Fig. 2a) or atosiban (Fig. 328 
2b) did not significantly reduce the mean of magnitude, activity integral, or frequency of 329 
contractions in spontaneously contracting strips.  In competition assays using oxytocin as 330 
agonist, however, the presence of increasing concentrations of retosiban evoked a right-ward 331 
shift in oxytocin concentration-response curve for peak (Fig. 3a), integral (Fig. 3b) and 332 
frequency (Fig. 3c). Similar observations were made with atosiban (Fig. 3d-f). EC50 values 333 
observed are displayed in table 1. 334 
Data from a phase 2 clinical trial suggest that retosiban may have a long acting mechanism of 335 
action [14].  To test whether retosiban remained active at the receptor for prolonged periods 336 
we challenged tissues with oxytocin immediately after washout of a preincubation with 337 
retosiban. The actions of retosiban were rapidly reversible. Removal of retosiban by washing 338 
and immediate addition of 100nM oxytocin resulted in contractile responses that were instant 339 
(Fig. 4a), and of similar magnitude to those preceding retosiban addition (Fig. 4b).  340 
To investigate potential for ligand bias (defined as a ligand specific selectivity for a 341 
downstream signaling pathway) from the OTR antagonists, we systematically investigated 342 
their mechanism of downstream signaling and potency. To confirm that any ligand bias was 343 
not simply a myometrial cell phenomenon we first tested the effect of the OTR antagonists on 344 
a Chinese Hamster Ovary cell line stably expressing the human oxytocin receptor.  Oxytocin 345 
generated concentration-dependent increases in IP-1 accumulation (Fig. 5a-c), a stable 346 
metabolite of IP3. Maximal responses were achieved at 100μM oxytocin with an EC50 value of 347 
-6.48±0.17 (332nM). The presence of increasing concentrations of retosiban (Fig. 5a), atosiban 348 
(Fig. 5b), and epelsiban an additional potent small molecule inhibitor of the OTR [22,23] 349 
provoked a right-ward curve shift (Fig. 5c), whereby increasing concentrations of oxytocin 350 
were required to illicit the same responses. pA2 values (the dose of antagonist needed to shift 351 
the agonist dose-response curve 2-fold to the right) were obtained using the Schild equation 352 
(Fig. 5d). Of the 3 antagonists, epelsiban was most potent with a pA2 value of -8.537, followed 353 
by retosiban -8.045 and finally atosiban -6.159. The data would indicate an increase in potency 354 
of inhibition of IP3 generation as approximately 77-fold for retosiban and 240-fold for 355 
epelsiban when compared to atosiban. Further analysis of Schild plots revealed slopes of 1.017, 356 
1.069 and 1.042 for epelsiban, retosiban and atosiban, respectively. pA2 and slope values are 357 
detailed in Table 2. 358 
To investigate IP3 production in intact tissue, uterine strips were treated with various 359 
compounds, and snap frozen either mid-way between or at the peak of contractions and IP3 360 
content determined. Initial comparisons of contraction versus inter-contraction interval 361 
demonstrated IP3 levels were essentially the same irrespective of contractions (Fig. 6a). By 362 
contrast 100nM oxytocin markedly increased IP3 levels (Fig. 6a), whilst IP3 was significantly 363 
reduced in the presence of 1μM retosiban (Fig. 6a). To investigate and confirm this effect 364 
further we increased the number of observations during peak contraction whereby retosiban 365 
again decreased IP3 when compared to vehicle control whereas IP3 levels in 10μM atosiban-366 
treated strips decreased but did not reach significance (Fig.6b).  367 
To further investigate downstream signaling and potential ligand bias at the OTR we 368 
challenged CHO-hOTR cells with either oxytocin, atosiban, retosiban or epelsiban and 369 
measured cAMP accumulation. None of the ligands elevated levels of cAMP (Fig. 7a), whereas 370 
addition of either forskolin or calcitonin, a selective Gαs-coupled receptor agonist, caused a 371 
robust and saturable elevation of cAMP accumulation. These data suggest that the OTR ligands 372 
do not signal through Gαs G-proteins in these cells.  373 
Both oxytocin and atosiban reduced calcitonin (Fig. 7b) and forskolin mediated cAMP 374 
production (Fig. 7c), providing evidence of Gαi-coupling. The potent and selective 5-HT1B 375 
(Gαi-coupled) agonist CP93129 [24] evoked similar changes. Importantly, neither retosiban 376 
nor epelsiban had any effect on cAMP. The oxytocin and atosiban mediated inhibition of 377 
cAMP were PTX sensitive demonstrating Gαi involvement (Fig. 7d). 378 
Stimulation of Gαi signaling in myometrial cells has the potential to activate ERK [25]. We 379 
therefore tested whether challenge of cultured myometrial cells taken at term cesarean section 380 
with either oxytocin or atosiban evoked an increase in ERK phosphorylation.  Application of 381 
either oxytocin or atosiban increased ERK activity in a concentration-dependent manner (Fig. 382 
8a) and generated EC50 values of -6.93 ± 0.34 (118nM) and -5.10 ± 0.32 (8.03µM) for oxytocin 383 
and atosiban respectively that peaked at ~5 min and subsequently declined (Fig. 8b). Cells did 384 
not respond to either controls, retosiban or epelsiban at equivalent receptor occupancy. 385 
Oxytocin and atosiban-mediated responses were inhibited by preincubation with pertussis 386 
toxin (PTX) (Fig. 8c).  387 
Increases in ERK activity in myometrial smooth muscle are associated with increased 388 
production of prostaglandins. We observed an increase in COX-2 (Fig. 9a) expression, and 389 
PGE2 (Fig. 9c) and PGF2 (Fig. 9d) secretion on challenge of spontaneously contracting 390 
myometrial strips with oxytocin and atosiban, but not retosiban or epelsiban. COX-2 391 
expression increased rapidly, but PGE2 and PGF2 secretion was absent until 2hr where a 3 to 392 
4-fold increase was observed. The magnitude of responses was similar for both oxytocin and 393 
atosiban. No increases in protein kinase A (PKA) activity were detected (except with the 394 
positive control forskolin), and no reduction in basal PKA levels were observed (Fig. 9b). 395 
PGE2 (Fig. 10a) and PGF2 (Fig. 10b) secretion was inhibited by PTX (Gαi inhibition), U0126 396 
(ERK inhibition) and rofecoxib (COX-2 inhibition). COX-2 expression was inhibited by PTX 397 
and U0126 (Fig. 10c).  398 
The downstream signaling analysis of the ligands suggested that contrary to atosiban being a 399 
neutral antagonist, it is in fact, an agonist at Gαi at micromolar concentrations. To investigate 400 
coupling of the OTR to specific Gα-subunits we utilised the [35S]-GTPγS immunoprecipitation 401 
assay in membrane preparations from cultured myometrial cells taken from patients at term. 402 
Oxytocin increased [35S]-GTPγS binding to Gαq/11 (Fig. 11a) G-proteins and both oxytocin and 403 
atosiban increased binding of Gαi subunits (Fig. 11b). Consistent with cAMP data no binding 404 
was observed following immunoprecipitation with Gαs G-proteins (Fig. 11c). Combined with 405 
signaling analysis these data confirm that at micromolar concentrations atosiban couples OTR 406 
to Gαi to elicit activation of ERK in human myometrial cells. Importantly, neither retosiban 407 
nor epelsiban elicited any increases in [35S]-GTPγS binding, signifying no agonist activity with 408 
these compounds.  409 
  410 
Discussion 411 
This study demonstrates that there are significant differences in the pharmacology of two small 412 
molecule OTR antagonists, retosiban and epelsiban, when compared to atosiban, a peptide 413 
antagonist licensed for use as a tocolytic for the treatment of preterm labour. The observations 414 
of this study, summarized in Figure 12 explain some, but not all, of the observed physiological 415 
effects of retosiban in the published literature.  In a phase 2 trial, administration of intravenous 416 
retosiban as a single dose was sufficient to inhibit spontaneous preterm birth by more than one 417 
week [14].  Our data suggest that it is highly unlikely that the long-lasting effect of the single 418 
dose was a consequence of continued action at the OTR, such as has been previously observed 419 
for the 2-adrenergic receptor agonist salmeterol [26], since antagonism of oxytocin stimulated 420 
contractions in uterine strips was rapidly reversible.  421 
All three antagonists tested in this study effectively inhibit OTR coupling to Gαq/11 and the 422 
generation of IP3, with epelsiban being the most potent, followed by retosiban and atosiban. 423 
Since stimulation of Ca2+ release from the sarcoplasmic reticulum by IP3 is the first component 424 
of the mechanism of oxytocin’s rapid action on the uterus [27] administration of all compounds 425 
should result in inhibition of the initial contractile effect.  In addition to an effect on oxytocin 426 
mediated IP3 signaling, the addition of retosiban reduced IP3 in intact strips under basal 427 
conditions.  Such a reduction is consistent with inverse agonism although it is difficult to rule 428 
out the presence of endogenous OT bound to recycled OTR in myometrial samples or 429 
endosomal signaling during altered trafficking.   430 
Previous work on atosiban has demonstrated that at micromolar concentrations the molecule 431 
acts as an agonist stimulating Gαi and causes inflammation in amnion cells [9,10]. In this study 432 
we demonstrated that in the myometrium atosiban at micromolar concentrations stimulates 433 
coupling of the OTR to Gαi and subsequent phosphorylation of ERK 1/2, COX2 upregulation, 434 
and PGE2 and PGF2 secretion. No such stimulation was observed with the addition of 435 
retosiban.  In CHO-OTR cells addition of micromolar atosiban or nanomolar oxytocin inhibited 436 
calcitonin and forskolin stimulated cAMP production, an effect that was prevented by addition 437 
of pertussis toxin, suggesting that the observed ligand bias is not cell specific. 438 
The functional consequences of the ligand bias of atosiban in vivo are hard to interpret without 439 
accurate tissue concentrations. Tissue concentrations that reach, or exceed, micromolar levels 440 
are likely to elicit inflammation and release of prostaglandins some hours after treatment. Thus, 441 
the tocolytic effect mediated by inhibition of Gαq/11 may initially be effective in inhibiting 442 
contractions but after some hours would paradoxically make contractions more likely via 443 
agonism of the OTR and stimulation of Gαi.  444 
We conclude that the small molecule oxytocin receptor antagonists retosiban and epelsiban 445 
inhibit downstream signaling in myometrial cells and CHO-hOTR cells in a manner consistent 446 
with that of a neutral antagonist. By contrast, the peptide based, mixed oxytocin/vasopressin 447 
V1a receptor antagonist Atosiban, inhibits oxytocin receptor signaling through the Gαq/11 g 448 
protein but acts as a partial agonist for signaling through the Gαi pathway. 449 
  450 
Tables. 451 
Table 1. 452 
Parameter Vehicle 1nM retosiban 3nM retosiban 10nM retosiban 30nM retosiban 100nM retosiban 300nM retosiban 1000nM retosiban
LogEC50  ± sem -8.67 ± 0.34 -9.34 ±  0.56 -9.484 ±  0.57 -9.345 ± 0.44 -9.302 ± 0.35 -8.251 ± 0.0.47 -8.771 ± 0.75 -8.546 ± 0.77
p value (mixed model ANOVA) ns ns ns ns 0.014 <0.0001 <0.0001 <0.0001
Emax ± sem 132 ± 3.49 123.9 ± 5.26 129.5 ± 5.78 129.2 ± 5.60 125.6 ± 6.66 118.3 ± 11.31 111.7 ± 9.07 107.7 ± 10.91
  CI  (LogEC50) -9.358 to -8.000 -10.42 to -8.281 -10.62 to -8.346 -10.18 to -8.573 -9.991 to -8.613 -9.197 to -7.305 -10.26 to -7.281 -10.07 to -7.024
Parameter Vehicle 1nM retosiban 3nM retosiban 10nM retosiban 30nM retosiban 100nM retosiban 300nM retosiban 1000nM retosiban
LogEC50  ± sem -8.354 ± 0.28 -8.641 ± 0.28 -8.489 ± 0.37 -8.614 ± 0.40 -8.269 ± 0.22 -8.048 ± 0.34 -8.159 ± 0.27 -7.575 ± 0.31
p value (mixed model ANOVA) ns ns ns ns <0.0001 <0.0001 <0.0001 <0.0001
Emax ± sem 414 ± 34.37 368.6 ± 30.69 366.7 ± 41.23 340 ± 38.85 331 ± 30.99 325.6 ± 53.21 302.3 ± 35.91 298 ± 54.06
  CI  (LogEC50) -8.908 to -7.801 -9.191 to -8.092 -9.229 to -7.750 -9.411 to -7.817 -8.714 to -7.823 -8.734 to -7.363 -8.706 to -7.612 -8.193 to -6.956
Parameter Vehicle 1nM retosiban 3nM retosiban 10nM retosiban 30nM retosiban 100nM retosiban 300nM retosiban 1000nM retosiban
LogEC50  ± sem -7.742 ± 0.53 -7.992 ± 0.36 -7.981 ± 0.30 -7.589 ± 0.50 -7.599 ± 0.50 -7.576 ± 0.49 -6.988 ± 1.16 -7.162 ± 1.51
p value (mixed model ANOVA) ns ns ns ns ns ns 0.0006 0.0036
Emax ± sem 228.3 ± 37.55 233.8 ± 26.61 235.6 ± 19.62 206 ± 34.48 201 ± 32.44 184.2 ± 39.62 194 ± 137.1 156 ± 743.67
  CI  (LogEC50) -8.802 to -6.683 -8.713 to -7.271 -8.580 to -7.382 -8.580 to -6.598 -8.597 to -6.601 -8.558 to -6.593 -9.292 to -4.684 -10.16 to -4.162
Parameter Vehicle 0.01µM Atosiban 0.03µM Atosiban 0.1µM Atosiban 0.3µM Atosiban 1µM Atosiban 3µM Atosiban 10µM Atosiban
LogEC50  ± sem -8.449 ± 0.20 -9.152 ± 0.40 -8.919 ± 0.31 -8.826 ± 0.24 -8.826 ± 0.34 -8.221 ± 0.40 -8.443 ± 0.49 -7.784 ± 0.58
p value (mixed model ANOVA) ns ns ns ns ns 0.0056 <0.0001 <0.0001
Emax ± sem 137.6 ± 3.3 135.8 ± 4.53 143.2 ± 4.54 139.6 ± 3.70 128 ± 5.24 126.4 ± 6.63 117.7 ± 7.43 118.3 ± 12.36
  CI  (LogEC50) -8.836 to -8.063 -9.949 to -8.355 -9.538 to -8.299 -9.298 to -8.354 -9.532 to -8.115 -9.025 to -7.417 -9.412 to -7.474 -8.947 to -6.622
Parameter Vehicle 0.01µM Atosiban 0.03µM Atosiban 0.1µM Atosiban 0.3µM Atosiban 1µM Atosiban 3µM Atosiban 10µM Atosiban
LogEC50  ± sem -8.327 ± 0.15 -8.835 ± 0.37 -9.121 ± 0.20 -8.932 ± 0.24 -8.47 ± 0.24 -8.239 ± 0.29 -8.071 ± 0.28 -7.97 ± 0.21
p value (mixed model ANOVA) ns ns ns ns ns 0.0057 <0.0001 <0.0001
Emax ± sem 410.6 ± 23.37 326.7 ± 27.41 346.3 ± 18.16 311.1 ± 19.23 296.7 ± 23.17 268 ± 26.54 222.3 ± 21.42 251.3 ± 22.02
  CI  (LogEC50) -8.624 to -8.029 -9.501 to -8.180 -9.519 to -8.723 -9.402 to -8.463 -8.952 to -7.987 -8.810 to -7.668 -8.627 to -7.516 -8.394 to -7.546
Parameter Vehicle 0.01µM Atosiban 0.03µM Atosiban 0.1µM Atosiban 0.3µM Atosiban 1µM Atosiban 3µM Atosiban 10µM Atosiban
LogEC50  ± sem -8.033 ± 0.31 -8.154 ± 0.45 -7.096 ± 0.47 -7.775 ± 0.25 -7.311 ± 0.65 -7.732 ± 0.67 -7.502 ± 0.36 -7.058 ± 1.21
p value (mixed model ANOVA) ns ns ns 0.0223 ns 0.0342 <0.0001 <0.0001
Emax ± sem 224.9 ± 18.36 225.3 ± 26.42 315.5 ± 106.4 214.6 ± 19.37 227.6 ± 70.24 179.4 ± 25.87 166.8 ± 17.99 178 ± 98.89
  CI  (LogEC50) -8.653 to -7.414 -9.055 to -7.254 -8.037 to -6.154 -8.276 to -7.274 -8.616 to -6.007 -8.874 to -6.574 -8.214 to -6.790 -9.467 to -4.649
Atosiban effects on contraction frequency (Fig 3f)
Retosiban effects on peak contractions (Fig 3a)
Retosiban effects on integral (Fig 3b)
Retosiban effects on contraction frequency (Fig 3c)
Atosiban effects on peak contractions (Fig 3d)




Table 2. 456 
Antagonist Epelsiban Retosiban Atosiban 
pA2 (Log10 M) -8.537 -8.045 -6.159 
pA2 (nM) 2.9 9.02 698.23 
Slope ± sem 1.017 ± 0.105 1.069 ± 0.105 1.042 ± 0.096 
 457 
  458 
Figure Legends: 459 
 460 
Figure 1. 461 
 (a) Representative trace showing phasic myometrial contractions in response to increasing 462 
concentrations of oxytocin (0.01nM-100nM). (b) Oxytocin (red square) concentration-463 
response curves. Data were analysed to assess the peak responses (peak-minimum), the area 464 
under the curve (integral) and the peak frequency (Hz) during the 10 min oxytocin stimulation. 465 
Data were expressed as a percentage increase over basal, unstimulated contractions in the 466 
presence of vehicle (black circle). Data revealed EC50 values of peak: -8.224 ± 0.46 (5.9nm), 467 
integral: -8.053 ± 0.13 (8.8nm) and peak frequency: -8.229 ± 0.16 (5.0nm). Data are mean ± 468 
s.e.m., n=3 (One-Way ANOVA and Dunnett's Multiple Comparison Test comparing oxytocin 469 
treatment to vehicle control, * P < 0.05, ** P < 0.01, *** P < 0.001) (c) Saturation binding in 470 
membranes prepared from myometrial biopsies incubated with varying concentrations of [3H]-471 
Oxytocin (0.01pM-100nM) either in the presence (non-specific binding) or absence (total 472 
binding) of 100nM unlabeled oxytocin. Bmax and KD
 were 8337 ± 931 fmol/mg protein, and 473 
24.15 ± 6.5nM, respectively. Data are mean ± s.e.m., n=6 474 
 475 
Figure 2. 476 
Spontaneously contracting myometrial biopsies were challenged with increasing 477 
concentrations of either retosiban (red square) (a) or atosiban (blue triangle) (b). Data were 478 
expressed as a percentage increase of basal, unstimulated contractions. Neither retosiban nor 479 
atosiban had significant effect on spontaneous contractions when compared to vehicle control 480 
(One-Way ANOVA and Dunnett's Multiple Comparison Test). Data are mean ± s.e.m., n=10  481 
 482 
Figure 3. 483 
Antagonist/agonist competition assays. Full oxytocin concentration-response curves were 484 
performed in the continued presence of either vehicle, or various concentrations of retosiban 485 
(0.001μM - 1μM) (a-c) or atosiban (0.01μM - 10μM) (d-f). Oxytocin doses were added for 10 486 
minutes and separated by a 20 minutes wash period during which the desired concentration of 487 
retosiban was continually present. Data were analysed in 10 minute blocks to assess the peak 488 
responses (peak-minimum) (a and d), the area under the curve (integral) (b and e) and the peak 489 
frequency (Hz) (c and f). Data were expressed as a percentage increase of basal, unstimulated 490 
contractions. Data are mean ± s.e.m., n=10 (data were analysed by mixed model ANOVA with 491 
antagonist as the between measures variable followed by Dunnett post hoc test comparing test 492 
antagonist concentration to vehicle, and P < 0.05 considered significant * P < 0.05, ** P < 493 
0.01, *** P < 0.001). EC50 and Emax values obtained are shown in table 1. 494 
 495 
Figure 4. 496 
Reversibility of retosiban antagonism (a) Representative traces showing the immediately 497 
reversible effects of 100nm oxytocin and 1µM retosiban on myometrial muscle strips. (b) Peak 498 
responses (peak-minimum), the area under the curve (integral) and the peak frequency (Hz) 499 
were expressed as a percentage increase of basal, unstimulated contractions. Colours and 500 
symbols denote paired observations within a biological replicate. Data are mean ± s.e.m., n=3 501 
(data were analysed by paired T-Test comparing observations before and after retosiban 502 
treatment, and P < 0.05 considered significant). 503 
 504 
Figure 5. 505 
Oxytocin-mediated IP-1 accumulation in CHO-hOTR cells. Cells were stimulated for 1hr with 506 
oxytocin in the presence of increasing concentrations of retosiban (a) atosiban (b) or epelsiban 507 
(c). Data are mean ± s.e.m, n=3 (data were analysed by mixed model ANOVA with antagonist 508 
as the between measures variable followed by Dunnett post hoc test comparing test antagonist 509 
concentration to vehicle, and P < 0.05 considered significant, * P < 0.05, ** P < 0.01, *** P < 510 
0.001). For Schild plot analysis of antagonist activity EC50 values were converted using Schild 511 
equation (Log (EC50 ratio-1) vs. Log [antagonist]) and pA2
 values obtained where y=0 (d). pA2 512 
and slope analysis values observed are indicated in table 2. 513 
 514 
Figure 6. 515 
IP3 levels in frozen muscle strips. (a) Tissues were frozen in LN2 between contractions 516 
(refractory period) or at the peak of contraction in the presence of vehicle, 1μM retosiban, 517 
10μM atosiban or 100nM oxytocin. IP3 levels in oxytocin-challenged muscle strips were 518 
significantly greater when compared to vehicle. The addition of 1μM retosiban significantly 519 
reduced IP3 when compared to vehicle. mean ± s.e.m., n=5 (data were analysed by one-way 520 
ANOVA followed by Dunnett post hoc test comparing test compound to vehicle, and P < 0.05 521 
considered significant. Refractory period and peak contraction were analysed separately, * P 522 
< 0.05, ** P < 0.01) (b) To confirm the observation that retosiban reduced IP3 levels in 523 
spontaneously contracting strips we repeated the experimental protocol in (a) with more 524 
numbers, measuring IP3 during the refractory period. Again, retosiban significantly reduced 525 
IP3. mean ± s.e.m., n=10. 526 
Figure 7. 527 
(a) CHO-hOTR cells were challenged with compounds for time points indicated and 528 
lysed.  Data are mean ± s.e.m., n=3. (b) CHO-hOTR cells were challenged simultaneously with 529 
compound and 10nM calcitonin for time points indicated before lysis. Inhibition of cAMP by 530 
oxytocin, atosiban and CP93129 (a potent and selective 5-HT1B receptor (Gαi-coupled) 531 
agonist) was significant when compared to calcitonin + vehicle. Data are mean ± s.e.m., n=3. 532 
(c) CHO-hOTR cells were stimulated with compounds for time points indicated before FSK 533 
challenge (10µM, 10min). Atosiban, oxytocin and CP93129 reduced FSK elevated cAMP 534 
when compared to vehicle. Data are mean ± s.e.m., n=3 (data were analysed by two-way 535 
ANOVA followed by Dunnett post hoc test comparing test compound time series to vehicle, 536 
and P < 0.05 considered significant, * P < 0.05, ** P < 0.01, *** P < 0.001). (d) As (c) but 537 
cells were treated with either 100ng/ml PTX or vehicle for 18hrs prior to stimulus. PTX pre-538 
treatment reversed the inhibition of cAMP production by oxytocin atosiban and CP93129. 539 
 540 
Figure 8. 541 
(a) Cultured human myometrial cells from term pregnant patients were challenged with 542 
compounds as indicated and phospho-ERK (Thr202/Tyr204) determined. Dose response of 543 
agonists at 5 mins for ERK activation. EC50 values were -6.93 ± 0.34 (118nM) and -5.10 ± 0.32 544 
(8.03µM) for oxytocin and atosiban respectively. Data are mean ± s.e.m., n=3 (data were 545 
analysed by one-way ANOVA followed by Dunnett post hoc test comparing test compound to 546 
vehicle, and P < 0.05 considered significant, * P < 0.05, ** P < 0.01). (b) Atosiban and 547 
oxytocin response time course. Data are mean ± s.e.m., n=3 (data were analysed by two-way 548 
ANOVA followed by Dunnett post hoc test comparing test compound time series to vehicle, 549 
and P < 0.05 considered significant, * P < 0.05, ** P < 0.01, *** P < 0.001). (c) As (b) but 550 
cultured cells were pre-treated for 18 hours with 100 ng/ml PTX. Data are mean ± s.e.m., n=3.  551 
 552 
Figure 9. 553 
Human myometrial strips were challenged with various OTR ligands for times indicated before 554 
homogenization. Expression of COX-2 (a) and PKA (b) in homogenates and concentrations of 555 
PGE2 (c) and PGF2 (d) in organ bath supernatant were determined. Data are mean ± s.e.m., 556 
n=3 (data were analysed by two-way ANOVA followed by Dunnett post hoc test comparing 557 
test compound time series to vehicle, and P < 0.05 considered significant, * P < 0.05, ** P < 558 
0.01, *** P < 0.001). 559 
 560 
Figure 10. 561 
Human myometrial strips were treated overnight with 100ng/ml PTX to inhibit Gαi, for 1hr 562 
with 10µM U0126 to inhibit ERK signalling, or 10µM rofecoxib to inhibit COX-2 before 563 
challenge with either oxytocin or atosiban as indicated. PGE2 (a) and PGF2  (b) within organ 564 
bath supernatant and COX-2 levels in tissue homogenates (c) were determined. Data are mean 565 
± s.e.m, n=3 (data were analysed by one-way ANOVA with atosiban and oxytocin analysed 566 
separately followed by Dunnett post hoc test comparing inhibitor compound to oxytocin or 567 
atosiban alone, and P < 0.05 considered significant, * P < 0.05, ** P < 0.01.) 568 
. 569 
 570 
Figure 11. 571 
Membranes prepared from cultured human myometrial cells were stimulated with various 572 
compounds for 2 min in the presence of [35S]-GTPγS and GDP. Activated membranes were 573 
incubated with antisera targeting Gαi (a), Gαi/o (b) and Gαs (c) G-proteins and with protein G-574 
Sepharose beads. NSB was determined by inclusion of 10µM unlabeled GTPγS. Data are mean 575 
± s.e.m., n=4 (data were analysed by one-way ANOVA followed by Dunnett post hoc test 576 
comparing test compound to vehicle, and P < 0.05 considered significant, * P < 0.05, ** P < 577 
0.01). 578 
 579 
Figure 12. 580 
Schematic representation of the ligands of this study and their downstream signaling pathways 581 
in myometrium. 582 
  583 
Abbreviations: AC: Adenylate Cyclase, ATP: Adenosine Trisphosphate, Ca2+: Calcium, 584 
cAMP: cyclic Adenosine Monophosphate, COX-2: Cyclo-oxygenase 2, DAG: Diacylglycerol, 585 
ERK 1/2: Extracellular Regulated Kinase 1/2, IP3: Inositol trisphosphate, MAP Kinase: 586 
Mitogen Activated Kinase, PIP2: Phosphatidylinositol 4,5-bisphosphate, PGE2: Prostaglandin 587 
E2, PGF2: Prostaglandin F2, PKA: Protein Kinase A, PKC: Protein Kinase C, PLC: 588 
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